Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Nutr ESPEN ; 51: 72-82, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-36184251

RESUMO

BACKGROUND & AIMS: Hypertension, dyslipidaemia, and chronic inflammation contribute to the development of cardiovascular disease (CVD). Zingiber officinale has been suggested to reduce these CVD risk factors; however, the clinical evidence remains unclear. This systematic review aims to analyse the effect of Z. officinale as a sole intervention on these risk factors. METHODS: In this PRISMA-based systematic review, we included randomised clinical trials from PubMed, Scopus and Cochrane Database of Systematic Reviews (July 2020) analysing triglycerides, low- and high-density lipoprotein (LDL, HDL), total cholesterol, C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin 1, 6, 10, systolic and/or diastolic blood pressure as outcomes. Quality of studies was evaluated by JADAD and the Cochrane risk-of-bias tools. RESULTS: A total of 24 studies were included, mostly (79.2%) showing low risk of bias. These were based on obesity and cardio-metabolic derangements (33.3%), type 2 diabetes mellitus (37.5%), and miscellaneous conditions (29.2%). While total cholesterol and triglycerides levels mostly improved after Z. officinale, results were inconsistent for other blood lipids markers. Inflammatory markers (CRP, TNF-α) were more consistently reduced by Z. officinale, while only 3 studies reported a non-significant reduction of blood pressure. CONCLUSIONS: Although there remains a paucity of studies, Z. officinale may be beneficial for improving dyslipidaemia and inflammation.


Assuntos
Doenças Cardiovasculares , Diabetes Mellitus Tipo 2 , Dislipidemias , Zingiber officinale , Pressão Sanguínea , Proteína C-Reativa , Doenças Cardiovasculares/prevenção & controle , Colesterol , Dislipidemias/tratamento farmacológico , Humanos , Inflamação/tratamento farmacológico , Interleucina-1 , Lipídeos , Lipoproteínas HDL , Triglicerídeos , Fator de Necrose Tumoral alfa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...